Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2015 Nov 19;6(11):e1982.
doi: 10.1038/cddis.2015.332.

Prospects of adjuvant RANKL inhibition in breast cancer?

T D Rachner  1 , P Wimberger  2 , L C Hofbauer  1   3
Affiliations
Comment

Prospects of adjuvant RANKL inhibition in breast cancer?

T D Rachner et al. Cell Death Dis. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

We have received grants or honorarium for advisory boards or lectures to the individual or the institution by Amgen (LCH, TDR and PW), Novartis (LCH, TDR and PW), Servier (LCH), Merck (LCH and TDR) and Nycomed (LCH, FJ), Roche (PW) and TEVA (PW). The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Impact of RANK/RANKL signaling on breast cancer. Progesterone receptor signaling in breast tissue results in a strong upregulation of RANKL expression. This is considered to mediate progestin-driven mammary carcinogenesis. Bone-derived RANKL promotes the migration of RANK expressing breast cancer cells to bone.
See this image and copyright information in PMC

Comment on

  • Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trial.
    Gnant M, Pfeiler G, Dubsky PC, Hubalek M, Greil R, Jakesz R, Wette V, Balic M, Haslbauer F, Melbinger E, Bjelic-Radisic V, Artner-Matuschek S, Fitzal F, Marth C, Sevelda P, Mlineritsch B, Steger GG, Manfreda D, Exner R, Egle D, Bergh J, Kainberger F, Talbot S, Warner D, Fesl C, Singer CF; Austrian Breast and Colorectal Cancer Study Group. Gnant M, et al. Lancet. 2015 Aug 1;386(9992):433-43. doi: 10.1016/S0140-6736(15)60995-3. Epub 2015 May 31. Lancet. 2015. PMID: 26040499 Clinical Trial.

References

    1. 1Hofbauer LC et al. Lancet Diabetes Endocrinol 2014; 2: 500–512. - PubMed
    1. 2Ellis GK et al. J Clin Oncol 2008; 26: 4875–4882. - PubMed
    1. 3Gnant M et al. Lancet 2015; 386: 433–443. - PubMed
    1. 4Schramek D et al. Nature 2010; 468: 98–102. - PMC - PubMed
    1. 5Gonzalez-Suarez E et al. Nature 2010; 468: 103–107. - PubMed

Substances